RAGIFILIMAB
UNII O440IW9NHN

Substance Identification & Data

This profile provides standardized clinical and technical data for Ragifilimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) O440IW9NHN.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2207590-51-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

O440IW9NHN

CAS Registry Number

2207590-51-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RAGIFILIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C126643

National Cancer Institute reference terminology for clinical and research data.

INN ID

11280

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-153

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ragifilimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RAGIFILIMAB

Common Names & Synonyms

ANTI-GITR AGONISTIC MONOCLONAL ANTIBODY INCAGN01876

IMMUNOGLOBULIN G1 (DE-448-LYSINE), ANTI-(HUMAN TUMOR NECROSIS FACTOR RECEPTOR TNFRSF18) (HUMAN-MUS MUSCULUS MONOCLONAL INCAGN01876.GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL INCAGN01876 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TNFRSF18 (TUMOR NECROSIS FACTOR RECEPTOR (TNFR) SUPERFAMILY MEMBER 18, ACTIVATION-INDUCIBLE TNFR FAMILY RECEPTOR, AITR, GLUCOCORTICOID-INDUCED TNFR-RELATED, GITR, CD375)), HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN HUMANIZED (1-447) (VH (HOMO SAPIENS IGHV1-2*02 (80.6%)-(IGHD)-IGHJ4*01 (92.9%)) CDR-IMGT (8.8.11) (26-33.51-58.97-107) (1-118)-HOMO SAPIENS IGHG1*03 (100%) G1M3, NG1M1 (CH1 R120 (215) (119-216), HINGE 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>DEL (447)) (119-447)), (221-220')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-220') (V-KAPPA (HOMO SAPIENS IGKV4-1*01 (91.1%)-IGKJ2*01 (100%)) CDR-IMGT (12.3.9) (27-38.56-58.95-103) (1'-113')-HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (159), V101 (197) (114'-220')); DIMER (227-227'':230-230'')-BISDISULFIDE; PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA

RAGIFILIMAB [INN]

RAGIFILIMAB [USAN]

RAGIFILIMAB [WHO-DD]